Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))
- Jacqueline S. Garcia
- , Ronan T. Swords
- , Gail J. Roboz
- , Meagan A. Jacoby
- , Guillermo Garcia-Manero
- , Wan Jen Hong
- , Xiaoqing Yang
- , Ying Zhou
- , Uwe Platzbecker
- , David P. Steensma
- , Johannes E. Wolff
- , Pierre Fenaux
Research output: Contribution to journal › Comment/debate